Humacyte falls after $20 million direct stock deal

Humacyte

19/03/2026 12:57

** Biotech firm Humacyte's HUMA.O shares falls 10.1% to $0.95 premarket

** Durham, North Carolina-based HUMA enters agreement with several new institutional investors to sell 25 million shares in a registered direct offering for gross proceeds of $20 million

** Offering led by a new life science dedicated investor and a long-only mutual fund - HUMA

** Implied offering price of $0.80 per share represents 24.5% upside to stock's last close

** Proceeds will be used to fund commercialization of its implant Symvess for patients with vascular trauma indication, among other purposes

** Titan Partners was sole placement agent for offering

** 6 of 7 brokerages rate the stock "buy" or higher and 1 "hold"; median PT $3.50 - data compiled by LSEG

** As of last close, HUMA stock up 10.4% YTD

 (Reporting by Arasu Kannagi Basil in Bengaluru)

 ((ArasuKannagi.Basil@thomsonreuters.com;))